BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.
Rachel RoyfmanEmma WhiteleyOlivia NoeSusan MorandJustin CreedenLaura StanberyDanae HamoudaJohn J NemunaitisPublished in: Future oncology (London, England) (2021)
Patients who have mutations of the genes BRCA1 or BRCA2 are at an increased risk for developing breast and ovarian cancer. BRCA1/2 function as tumor suppressor genes, responsible for regulating DNA repair, and play an essential role in homologous recombination. Mutation of BRCA1/2 results in homologous recombination deficiency and genomic instability which drives oncogenesis and cancer proliferation. Recently, BRCA1/2 gene expression has been implicated in regulating immune response. Here we discuss the signaling pathway of BRCA1/2 in relation to breast and ovarian cancer, with emphasis on how dysregulation facilitates the path to malignancy and current treatment options.
Keyphrases
- dna repair
- dna damage
- gene expression
- breast cancer risk
- signaling pathway
- immune response
- dna damage response
- end stage renal disease
- dna methylation
- chronic kidney disease
- ejection fraction
- newly diagnosed
- dendritic cells
- young adults
- epithelial mesenchymal transition
- prognostic factors
- toll like receptor
- peritoneal dialysis